Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000220660 | SCV000275569 | uncertain significance | Hereditary cancer-predisposing syndrome | 2015-05-04 | criteria provided, single submitter | clinical testing | The p.S666P variant (also known as c.1996T>C), located in coding exon 17 of the NF1 gene, results from a T to C substitution at nucleotide position 1996. The serine at codon 666 is replaced by proline, an amino acid with similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. To date, this alteration has been detected with an allele frequency of approximately 0.002% (greater than 55000 alleles tested) in our clinical cohort. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of p.S666P remains unclear. |
| Labcorp Genetics |
RCV003495120 | SCV004298560 | uncertain significance | Neurofibromatosis, type 1 | 2024-04-29 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 666 of the NF1 protein (p.Ser666Pro). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with NF1-related conditions. ClinVar contains an entry for this variant (Variation ID: 231657). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt NF1 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV004558519 | SCV005047574 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2021-03-18 | criteria provided, single submitter | clinical testing | The c.1996T>C (p.S666P) alteration is located in exon 17 (coding exon 17) of the NF1 gene. This alteration results from a T to C substitution at nucleotide position 1996, causing the serine (S) at amino acid position 666 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |